With An Eye On China’s Growing PAD Market, SciClone Teams Up With Taiwan Liposome Co.
This article was originally published in PharmAsia News
Looking to take on Bayer/UCB’s Prostavasin and a local blockbuster from Beijing Tide Pharmaceutical Co., SciClone will jump into China’s peripheral arterial disease market with what it hopes is a differentiated product developed by TLC.
You may also be interested in...
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.